Health ❯ Healthcare ❯ Medical Research ❯ Oncology

Pancreatic Cancer

Can‑Fite Reports Safe Phase 2a Readout and Survival Signals for Namodenoson in Advanced Pancreatic Cancer

The company plans a Phase 2b trial combining Namodenoson with chemotherapy to test preclinical evidence that the drug increases tumor chemosensitivity.

4 ARTICLES

2mo ago

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

12 ARTICLES

2mo ago

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

35 ARTICLES

2mo ago

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

11 ARTICLES

3mo ago

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

8 ARTICLES

4mo ago

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

16 ARTICLES

6mo ago

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

3 ARTICLES

7mo ago

Splice-Switching ASO Collapses Oncogenic Circuit in Pancreatic Cancer Models